Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement < 7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT)
单位：[1]Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, P.R. China[2]The George Institute for Global Health at Peking University Health Science Center, Beijing, P.R. China[3]Department of Endocrinology, The First Affiliated Hospital, Division of life sciences and medicine, University of Science and Technology of China, Hefei, China[4]Department of Endocrinology, The General Hospital of the People's Liberation Army, Beijing, P.R. China[5]Department of Endocrinology, Peking University First Hospital, Beijing, P.R. China[6]Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, P.R. China.[7]Department of Endocrinology, China-Japan Friendship Hospital, Beijing, P.R. China.[8]Department of Endocrinology, The Second Military Medical University, Shanghai, P.R. China.[9]Department of Endocrinology, Xiangya Second Hospital, Changsha, P.R. China.[10]Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.[11]School of Public Health, The University of Queensland, Brisbane, QLD, Australia
Background The efficacy of basal insulin (BI) for adequate glycemic control in patients with type 2 diabetes mellitus (T2DM) has been well documented by randomized clinical trials. This post hoc analysis of the Observational Registry of Basal Insulin Treatment (ORBIT) study was performed to explore the 6-month dose of BI used in insulin-naive T2DM patients achieving HbA1c target (<7%) and determine the patient characteristics that affect the 6-month dose of BI in the setting of real-world clinics in China. Methods This multicenter observational registry screened 19 894 adult T2DM patients with inadequately controlled hyperglycemia and treated with oral antidiabetic drugs (OADs) in China. Of these patients, 5191 who continued to receive BI after 6 months and achieved HbA1c target were analyzed. Patient characteristics including age, body weight, fasting plasma glucose (FPG), use of OADs, insulin (type and dose), and glycemic control were recorded at baseline and 6-month follow-ups. Results The 6-month dose of BI needed for effective glycemic control was 0.20 +/- 0.08 U/kg/day. High body mass index, high FPG, young age, longer duration of diabetes or OAD treatment, a greater number of OADs at baseline, and allocation to detemir and glargine were significant independent predictors for high dose of BI at 6 months. Conclusions This post hoc analysis of the ORBIT registry provides key information on the 6-month dose of BI needed for effective glycemic control in Chinese T2DM patients. Furthermore, it identified crucial patient characteristics that are significant determinants of the dose of BI in a real-world setting.
第一作者单位：[1]Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, P.R. China
通讯作者：
通讯机构：[1]Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, P.R. China[*1]Department of Endocrine and Metabolic Diseases, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, China ,100044
推荐引用方式(GB/T 7714)：
Gao Leili,Zhang Puhong,Weng Jianping,et al.Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement < 7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT)[J].JOURNAL of DIABETES.2020,12(9):668-676.doi:10.1111/1753-0407.13046.
APA：
Gao, Leili,Zhang, Puhong,Weng, Jianping,Lu, Juming,Guo, Xiaohui...&Ji, Linong.(2020).Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement < 7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).JOURNAL of DIABETES,12,(9)
MLA：
Gao, Leili,et al."Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement < 7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT)".JOURNAL of DIABETES 12..9(2020):668-676
